59008 Federal Register / Vol. 78, No. 186 / Wednesday, September 25, 2013 / Notices 

through the Information Collection 

Review page at www.reginfo.gov. 

Paper copies can be obtained by: 

• Email: InformationCollection@

uspto.gov. Include ‘‘0651–0022 copy 

request’’ in the subject line of the 

message. 

• Mail: Susan K. Fawcett, Records 

Officer, Office of the Chief Information 

Officer, United States Patent and 

Trademark Office, P.O. Box 1450, 

Alexandria, VA 22313–1450. 

Written comments and 

recommendations for the proposed 

information collection should be sent on 

or before October 25, 2013 to Nicholas 

A. Fraser, OMB Desk Officer, via email 

to Nicholas_A_Fraser@omb.eop.gov or 

by fax to 202–395–5167, marked to the 

attention of Nicholas A. Fraser. 

Dated: September 20, 2013. 

Susan K. Fawcett, 

Records Officer, USPTO, Office of the Chief 

Information Officer. 

[FR Doc. 2013–23294 Filed 9–24–13; 8:45 am] 

BILLING CODE 3510–16–P 

DEPARTMENT OF COMMERCE 

United States Patent and Trademark 

Office 

[Docket No.: PTO–P–2013–0048] 

Grant of Interim Extension of the Term 

of U.S. Patent No. 5,624,923; Lixivaptan 

AGENCY: United States Patent and 

Trademark Office, Commerce. 

ACTION: Notice of Interim Patent Term 

Extension. 

SUMMARY: The United States Patent and 

Trademark Office has issued an order 

granting interim extension under 35 

U.S.C. 156(d)(5) for a one-year interim 

extension of the term of U.S. Patent No. 

5,624,923. 

FOR FURTHER INFORMATION CONTACT: 

Mary C. Till by telephone at (571) 272– 

7755; by mail marked to her attention 

and addressed to the Commissioner for 

Patents, Mail Stop Hatch-Waxman PTE, 

P.O. Box 1450, Alexandria, VA 22313– 

1450; by fax marked to her attention at 

(571) 273–7755; or by email to 

Mary.Till@uspto.gov. 

SUPPLEMENTARY INFORMATION: Section 

156 of Title 35, United States Code, 

generally provides that the term of a 

patent may be extended for a period of 

up to five years if the patent claims a 

product, or a method of making or using 

a product, that has been subject to 

certain defined regulatory review, and 

that the patent may be extended for 

interim periods of up to one year if the 

regulatory review is anticipated to 

extend beyond the expiration date of the 

patent. 

On July 11, 2013, Cardiokine 

Biopharma, LLC timely filed an 

application under 35 U.S.C. 156(d)(5) 

for an interim extension of the term of 

U.S. Patent No. 5,624,923. The patent 

claims the human drug product 

lixivaptan. The application indicates 

that a New Drug Application, 203,009, 

for the drug product lixivaptan was filed 

on December 29, 2011, and is currently 

undergoing regulatory review before the 

Food and Drug Administration for 

permission to market or use the product 

commercially. 

Review of the application indicates 

that, except for permission to market or 

use the product commercially, the 

subject patent would be eligible for an 

extension of the patent term under 35 

U.S.C. 156, and that the patent should 

be extended for one year as required by 

35 U.S.C. 156(d)(5)(B). Because the 

regulatory review period has continued 

beyond the original expiration date of 

the patent, July 29, 2013, interim 

extension of the patent term under 35 

U.S.C. 156(d)(5) is appropriate. 

An interim extension under 35 U.S.C. 

156(d)(5) of the term of U.S. Patent No. 

5,624,923 is granted for a period of one 

year from the original expiration date of 

the patent. 

Dated: September 20, 2013. 

Andrew Hirshfeld, 

Deputy Commissioner for Patent Examination 

Policy, United States Patent and Trademark 

Office. 

[FR Doc. 2013–23325 Filed 9–24–13; 8:45 am] 

BILLING CODE 3510–16–P 

DEPARTMENT OF COMMERCE 

United States Patent and Trademark 

Office 

[Docket No.: PTO–P–2013–0047] 

Grant of Interim Extension of the Term 

of U.S. Patent No. 5,454,779; 

ResQPump®/ResQPOD® ITD 

AGENCY: United States Patent and 

Trademark Office, Commerce. 

ACTION: Notice of Interim Patent Term 

Extension. 

SUMMARY: The United States Patent and 

Trademark Office has issued a second 

order granting interim extension under 

35 U.S.C. 156(d)(5) for a one-year 

interim extension of the term of U.S. 

Patent No. 5,454,779. 

FOR FURTHER INFORMATION CONTACT: 

Mary C. Till by telephone at (571) 272– 

7755; by mail marked to her attention 

and addressed to the Commissioner for 

Patents, Mail Stop Hatch-Waxman PTE, 

P.O. Box 1450, Alexandria, VA 22313– 

1450; by fax marked to her attention at 

(571) 273–7755; or by email to 

Mary.Till@uspto.gov. 

SUPPLEMENTARY INFORMATION: Section 

156 of Title 35, United States Code, 

generally provides that the term of a 

patent may be extended for a period of 

up to five years if the patent claims a 

product, or a method of making or using 

a product, that has been subject to 

certain defined regulatory review, and 

that the patent may be extended for 

interim periods of up to one year if the 

regulatory review is anticipated to 

extend beyond the expiration date of the 

patent. 

On August 21, 2013, the Regents of 

the University of California timely filed 

an application under 35 U.S.C. 156(d)(5) 

for a second interim extension of the 

term of U.S. Patent No. 5,454,779. The 

patent claims the medical device, 

ResQPump® in connection with the 

ResQPOD® ITD. The application 

indicates that a Premarket Approval 

Application, PMA No. P110024, for the 

medical device has been filed, and is 

currently undergoing regulatory review 

before the Food and Drug 

Administration for permission to market 

or use the product commercially. 

Review of the application indicates 

that, except for permission to market or 

use the product commercially, the 

subject patent would be eligible for an 

extension of the patent term under 35 

U.S.C. 156, and that the patent should 

be extended for one year as required by 

35 U.S.C. 156(d)(5)(B). Because it is 

apparent that the regulatory review 

period will continue beyond the 

extended expiration date of the patent, 

October 3, 2013, interim extension of 

the patent term under 35 U.S.C. 

156(d)(5) is appropriate. 

An interim extension under 35 U.S.C. 

156(d)(5) of the term of U.S. Patent No. 

5,454,779 is granted for a period of one 

year from the extended expiration date 

of the patent. 

Dated: September 20, 2013. 

Andrew Hirshfeld, 

Deputy Commissioner for Patent Examination 

Policy, United States Patent and Trademark 

Office. 

[FR Doc. 2013–23327 Filed 9–24–13; 8:45 am] 

BILLING CODE 3510–16–P 

COMMODITY FUTURES TRADING 

COMMISSION 

Sunshine Act Meeting 

TIME AND DATE: 10:00 a.m., Friday, 

October 18, 2013 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 78, No. 186 / Wednesday, September 25, 2013 / Notices 59009 

PLACE: 1155 21st St. NW., Washington, 

DC, 9th Floor Commission Conference 

Room 

STATUS: Closed. 

MATTERS TO BE CONSIDERED: 

Surveillance, Enforcement Matters, and 

Examinations. In the event that the 

times or dates of this or any future 

meetings change, an announcement of 

the change, along with the new time and 

place of the meeting will be posted on 

the Commission’s Web site at http://

www.cftc.gov. 

CONTACT PERSON FOR MORE INFORMATION: 

Melissa D. Jurgens, 202–418–5516. 

Natise Stowe, 

Executive Assistant. 

[FR Doc. 2013–23417 Filed 9–23–13; 11:15 am] 

BILLING CODE 6351–01–P 

COMMODITY FUTURES TRADING 

COMMISSION 

Sunshine Act Meeting 

TIME AND DATE: 10:00 a.m., Friday, 

October 4, 2013. 

PLACE: 1155 21st St. NW., Washington, 

DC, 9th Floor Commission Conference 

Room. 

STATUS: Closed. 

MATTERS TO BE CONSIDERED: 

Surveillance, Enforcement Matters, and 

Examinations. In the event that the 

times, dates or locations of this or any 

future meetings change, an 

announcement of the change, along with 

the new time, and place of the meeting 

will be posted on the Commission’s 

Web site at http://www.cftc.gov. 

CONTACT PERSON FOR MORE INFORMATION: 

Melissa D. Jurgens, 202–418–5516. 

Natise Stowe, 

Executive Assistant. 

[FR Doc. 2013–23415 Filed 9–23–13; 11:15 am] 

BILLING CODE 6351–01–P 

COMMODITY FUTURES TRADING 

COMMISSION 

Sunshine Act Meeting 

TIME AND DATE: 10:00 a.m., Friday, 

October 11, 2013 

PLACE: 1155 21st St. NW., Washington, 

DC, 9th Floor Commission Conference 

Room 

STATUS: Closed. 

MATTERS TO BE CONSIDERED: 

Surveillance, Enforcement Matters, and 

Examinations. In the event that the 

times or dates of this or any future 

meetings change, an announcement of 

the change, along with the new time and 

place of the meeting will be posted on 

the Commission’s Web site at http://

www.cftc.gov. 

CONTACT PERSON FOR MORE INFORMATION: 

Melissa D. Jurgens, 202–418–5516. 

Natise Stowe, 

Executive Assistant. 

[FR Doc. 2013–23416 Filed 9–23–13; 11:15 am] 

BILLING CODE 6351–01–P 

COMMODITY FUTURES TRADING 

COMMISSION 

Sunshine Act Meeting 

TIME AND DATE: 10:00 a.m., Friday, 

October 25, 2013 

PLACE: 1155 21st St. NW., Washington, 

DC, 9th Floor Commission Conference 

Room 

STATUS: Closed. 

MATTERS TO BE CONSIDERED: 

Surveillance, Enforcement Matters, and 

Examinations. In the event that the 

times, dates, or locations of this or any 

future meetings change, an 

announcement of the change, along with 

the new time, date and place of the 

meeting will be posted on the 

Commission’s Web site at http://

www.cftc.gov. 

CONTACT PERSON FOR MORE INFORMATION: 

Melissa D. Jurgens, 202–418–5516. 

Natise Stowe, 

Executive Assistant. 

[FR Doc. 2013–23418 Filed 9–23–13; 11:15 am] 

BILLING CODE 6351–01–P 

DEPARTMENT OF DEFENSE 

GENERAL SERVICES 

ADMINISTRATION 

NATIONAL AERONAUTICS AND 

SPACE ADMINISTRATION 

[OMB Control No. 9000–0012; Docket 2013– 

0077; Sequence 11] 

Information Collection; OMB Control 

No. 9000–0012, Termination Settlement 

Proposal Forms—FAR (Standard 

Forms 1435 Through 1440) 

AGENCY: Department of Defense (DOD), 

General Services Administration (GSA), 

and National Aeronautics and Space 

Administration (NASA). 

ACTION: Notice of request for public 

comments regarding an extension, with 

changes, to an existing OMB clearance. 

SUMMARY: Under the provisions of the 

Paperwork Reduction Act, the 

Regulatory Secretariat will be 

submitting to the Office of Management 

and Budget (OMB) a request to review 

and approve an extension of a 

previously approved information 

collection requirement concerning 

Termination Settlement Proposal 

Forms—FAR (Standard Forms 1435 

through 1440), as prescribed at FAR 

subpart 49.6, Contract Termination 

Forms and Formats. 

DATES: Submit comments on or before 

November 25, 2013. 

ADDRESSES: Submit comments 

identified by Information Collection 

9000–0012 by any of the following 

methods: 

• Regulations.gov: http:// 

www.regulations.gov. Submit comments 

via the Federal eRulemaking portal by 

inputting ‘‘Information Collection 9000– 

0012’’ under the heading ‘‘Enter 

Keyword or ID’’ and selecting ‘‘Search’’. 

Select the link ‘‘Submit a Comment’’ 

that corresponds with ‘‘Information 

Collection 9000–0012’’. Follow the 

instructions provided at the ‘‘Submit a 

Comment’’ screen. Please include your 

name, company name (if any), and 

‘‘Information Collection 9000–0012’’ on 

your attached document. 

• Fax: 202–501–4067. 

• Mail: General Services 

Administration, Regulatory Secretariat 

(MVCB), 1800 F Street NW., 2nd Floor, 

Washington, DC 20405–0001. ATTN: 

Hada Flowers/IC 9000–0012. 

Instructions: Please submit comments 

only and cite Information Collection 

9000–0012, in all correspondence 

related to this collection. Submit 

comments regarding this burden 

estimate or any other aspect of this 

collection of information, including 

suggestions for reducing this burden to: 

FAR Desk Officer. All comments 

received will be posted without change 

to http://www.regulations.gov, including 

any personal and/or business 

confidential information provided. 

FOR FURTHER INFORMATION CONTACT: Mr. 

Curtis E. Glover, Procurement Analyst, 

Federal Acquisition Policy Division, at 

(202) 501–1448 or Curtis.glover@

gsa.gov. 

SUPPLEMENTARY INFORMATION: 

A. Purpose 

The termination settlement proposal 

forms (Standard Forms 1435 through 

1440) provide a standardized format for 

listing essential cost and inventory 

information needed to support the 

terminated contractor’s negotiation 

position per FAR subpart 49.6— 

Contract Termination Forms and 

Formats. Submission of the information 

assures that a contractor will be fairly 

mstockstill on DSK4VPTVN1PROD with NOTICES